Tempus AI, Inc. (TEM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Tempus AI CEO Eric Lefkofsky described second-quarter and year-to-date performance as strong and broad-based, led by durable demand in its core diagnostics business. Comprehensive genomic profiling, including solid-tumor profiling and liquid biopsy, is seeing unit growth alongside rising average selling prices, while the higher-growth MRD business provides an additional growth vector. The commentary supports a constructive outlook for Tempus' largest revenue segment, although no specific financial results or guidance figures were provided in the excerpt.

Analysis

The investable issue for TEM is whether higher-value genomic testing is becoming a durable mix shift rather than a volume rebound. If reimbursement and oncologist ordering behavior support both test-volume growth and pricing, incremental gross profit should scale faster than revenue because laboratory fixed costs and data infrastructure are already largely in place. That would justify multiple expansion over the next 6-18 months, but only if the company converts diagnostic growth into improving adjusted EBITDA and operating cash flow rather than reinvesting all gross-profit upside into AI initiatives and sales capacity.

Near-term, the conference commentary is unlikely to be a standalone catalyst after a strong quarter; the more important 1-3 month read-through is whether peers in precision oncology and liquid biopsy validate stable utilization. Guardant Health (GH) is the most relevant public read-through: accelerating testing demand would support the category, while a GH reimbursement, pricing, or volume miss would challenge the assumption that TEM-specific growth is insulated from broader oncology-testing budgets. Exact Sciences (EXAS) is a weaker but useful proxy for payer scrutiny across molecular diagnostics.

Consensus may be underestimating the tension between TEM's data/AI narrative and diagnostic economics. A larger testing footprint improves the proprietary data asset, but monetization from data licensing, clinical-trial matching, and software carries long sales cycles and potentially lower near-term margins than investors may model. The bullish thesis is falsified if core diagnostic revenue growth decelerates for two consecutive quarters, gross margin fails to expand despite mix improvement, or management raises operating-expense guidance faster than revenue; absent those signals, pullbacks around sector risk-off days are more attractive than chasing conference-driven strength.

Key Decisions for Investors

• Maintain a modest long TEM only on pullbacks of 8-12% from post-conference levels, with a 6-12 month horizon. Underwrite upside to sustained diagnostic mix-driven margin expansion; exit or reduce if the next two reports show flat-to-down gross margin alongside elevated opex.
• Use a 1-3 month relative-value monitor: long TEM / short GH only if TEM demonstrates superior revenue growth and margin conversion at its next earnings release while GH shows category-level reimbursement or utilization pressure. This is a watch item, not an immediate trade, because current valuation spreads and short borrow are required to size the pair.
• Do not treat the AI platform narrative as incremental earnings until management discloses contract value, renewal rates, and gross margin for non-diagnostic revenue. Set an alert for guidance that separates diagnostic growth from data/software monetization; quantified recurring software revenue would be a catalyst for increasing the TEM long.
• For existing TEM exposure, consider trimming into a sharp pre-earnings multiple expansion and retaining upside through a defined-risk call spread rather than outright stock. The risk/reward deteriorates if the share price rerates before evidence of cash-flow conversion, since reimbursement and laboratory-utilization disappointments can compress diagnostics multiples quickly.